In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

The invention relates to an organic molecule having precisely two units of formula I linked to one another via a single bond or a bridge Y

##STR00001##

where
Y=a divalent group;
X=at each occurrence identically or differently CN and CF.sub.3;
D=chemical unit having a structure of the formula I-1:

##STR00002##

where
#=attachment point of the unit of formula I-1 to the structure of formula I;
A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z;
Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof,
wherein m, n, p, q, r, A, W, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof,
wherein m, n, p, q, r, A, W, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Compounds of the formula I:

##STR00001##

or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Compounds of the formula I:

##STR00001##

or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.